These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 24898712)

  • 1. Prevalence of hepatitis B virus infection in patients with rheumatic diseases in Tohoku area: a retrospective multicenter survey.
    Watanabe R; Ishii T; Kobayashi H; Asahina I; Takemori H; Izumiyama T; Oguchi Y; Urata Y; Nishimaki T; Chiba K; Komatsuda A; Chiba N; Miyata M; Takagi M; Kawamura O; Kanno T; Hirabayashi Y; Konta T; Ninomiya Y; Abe Y; Murata Y; Saito Y; Ohira H; Harigae H; Sasaki T
    Tohoku J Exp Med; 2014 Jun; 233(2):129-33. PubMed ID: 24898712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment Screening for Hepatitis B Virus Infection in Patients with Systemic Lupus Erythematosus.
    Watanabe R; Ishii T; Harigae H
    Tohoku J Exp Med; 2015 Sep; 237(1):9-15. PubMed ID: 26288957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy.
    Harigai M; Mochida S; Mimura T; Koike T; Miyasaka N
    Mod Rheumatol; 2014 Jan; 24(1):1-7. PubMed ID: 24261752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving immunosuppressive therapy for glomerulonephritis: a retrospective analysis.
    Fang J; Li W; Peng X; Tan Z; Tan M; Zhang C; Wang W; Xu Z; Zhou G
    Int Urol Nephrol; 2017 Mar; 49(3):475-482. PubMed ID: 28032257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study.
    Tien YC; Yen HH; Li CF; Liu MP; Hsue YT; Hung MH; Chiu YM
    Arthritis Res Ther; 2018 Nov; 20(1):246. PubMed ID: 30382902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and time course of hepatitis B virus infection in patients with systemic lupus erythematosus under immunosuppressive therapy.
    Watanabe R; Ishii T; Nakamura K; Shirai T; Tajima Y; Fujii H; Harigae H
    Mod Rheumatol; 2013 Nov; 23(6):1094-100. PubMed ID: 23180323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan.
    Fukuda W; Hanyu T; Katayama M; Mizuki S; Okada A; Miyata M; Handa Y; Hayashi M; Koyama Y; Arii K; Kitaori T; Hagiyama H; Urushidani Y; Yamasaki T; Ikeno Y; Suzuki T; Omoto A; Sugitani T; Morita S; Inokuma S
    Ann Rheum Dis; 2017 Jun; 76(6):1051-1056. PubMed ID: 27934678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low prevalence of hepatitis B virus infection in patients with systemic lupus erythematosus in southern China.
    Zhao J; Qiu M; Li M; Lu C; Gu J
    Rheumatol Int; 2010 Nov; 30(12):1565-70. PubMed ID: 19826817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of Chronic Hepatitis B Infection in Patients with Systemic Lupus Erythematosus: Viral Reactivation and Impact on Disease Activity.
    Sumethkul K; Srivitidkul S
    J Med Assoc Thai; 2017 Feb; 100 Suppl 1():S124-30. PubMed ID: 29927230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B Virus Infection Rate and Distribution in Chinese Systemic Lupus Erythematosus Patients.
    Chen X; Hong L; Zhang W; Yuan M; Yang Q; Mao H; Chen W; Yu X
    Med Sci Monit; 2015 Jul; 21():1955-9. PubMed ID: 26148056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.
    Lee YH; Bae SC; Song GG
    Clin Exp Rheumatol; 2013; 31(1):118-21. PubMed ID: 23111095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updates on management strategies of hepatitis B virus reactivation in patients with resolved hepatitis virus B infection undergoing immunosuppressive therapy in rheumatology and the current situation in Niigata Rheumatic Center.
    Ito S
    Mod Rheumatol; 2021 Jul; 31(4):775-782. PubMed ID: 33021133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis of hepatitis B reactivation with immunosuppressive therapy in rheumatic diseases. Orientations for clinical practice.
    Nunes J; Marinho RT; Fonseca JE; Pereira da Silva JA; Velosa J
    Acta Reumatol Port; 2011; 36(2):110-8. PubMed ID: 21841730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B infection and changes in interferon-alpha and -gamma production in patients with systemic lupus erythematosus in Taiwan.
    Lu CL; Tsai ST; Chan CY; Hwang SJ; Tsai CY; Wu JC; Lu RH; Lin BC; Lee SD
    J Gastroenterol Hepatol; 1997 Apr; 12(4):272-6. PubMed ID: 9195365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases.
    Kim YJ; Bae SC; Sung YK; Kim TH; Jun JB; Yoo DH; Kim TY; Sohn JH; Lee HS
    J Rheumatol; 2010 Feb; 37(2):346-50. PubMed ID: 20008922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection].
    Sato K
    Gan To Kagaku Ryoho; 2011 Feb; 38(2):161-8. PubMed ID: 21368477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.
    Lee YH; Bae SC; Song GG
    Int J Rheum Dis; 2013 Oct; 16(5):527-31. PubMed ID: 24164839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus infection in patients with systemic lupus erythematosus.
    Chng HH; Fock KM; Chew CN; Guan R; Feng PH; Boey ML; Chee EN; Chua KL
    Singapore Med J; 1993 Aug; 34(4):325-6. PubMed ID: 8266204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review.
    Xuan D; Yu Y; Shao L; Wang J; Zhang W; Zou H
    Clin Rheumatol; 2014 Apr; 33(4):577-86. PubMed ID: 24343455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.